American Institute of Mathematical Sciences

Advanced
  • Previous Article
    Attractors and entropy bounds for a nonlinear RDEs with distributed delay in unbounded domains
  • DCDS-B Home
  • This Issue
  • Next Article
    Global well-posedness and asymptotic behavior of solutions to a reaction-convection-diffusion cholera epidemic model
June  2016, 21(4): 1279-1295. doi: 10.3934/dcdsb.2016.21.1279

Mathematical and numerical analysis of a mathematical model of mixed immunotherapy and chemotherapy of cancer

Hsiu-Chuan Wei 1,

1. 

Department of Applied Mathematics, Feng Chia University, Seatwen, Taichung 40724, Taiwan

Received  January 2015 Revised  November 2015 Published  March 2016

In this study, a previously published mathematical model of mixed immunotherapy and chemotherapy of tumors is considered. The stability analysis of the tumor-free equilibrium obtained in the previous study of this model is flawed. In this paper, a suitable analysis is performed to correct this error, and the parameter conditions for the stability of the tumor-free equilibrium are obtained. The stability condition gives an indicator of the host's ability to fight a cancer. The parameter conditions are examined using experimental data from clinical studies to show that the immune system is able to control a small tumor, and the host's ability to fight a cancer depends on individual variation. A numerical method based on the continuation technique is employed for one-parameter bifurcation analysis of the mathematical model with periodically pulsed therapies. The unstable fixed point curve provides a good approximation of the maximum tumor burden as a function of the dosage. Chemotherapy-induced lymphocyte damage, which may cause treatment failure, is observed in the numerical simulation. The numerical method also produces a set of combined chemotherapy and immunotherapy dosages from which an efficient and safe combination of dosages can be determined.
Keywords: Cancer therapy, mathematical analysis, impulsive differential equation, bifurcation analysis, numerical simulation..
Mathematics Subject Classification: Primary: 37N25, 34H20, 92B05; Secondary: 34D2.
Citation: Hsiu-Chuan Wei. Mathematical and numerical analysis of a mathematical model of mixed immunotherapy and chemotherapy of cancer. Discrete & Continuous Dynamical Systems - B, 2016, 21 (4) : 1279-1295. doi: 10.3934/dcdsb.2016.21.1279
References:
[1]

N. Almog, Molecular mechanisms underlying tumor dormancy,, Cancer Lett., 294 (2010), 139. doi: 10.1016/j.canlet.2010.03.004.

[2]

A. J. Barrett and B. N. Savani, Does chemotherapy modify the immune surveillance of hematological malignancies?, Leukemia, 23 (2009), 53. doi: 10.1038/leu.2008.273.

[3]

M. J. Besser, R. Shapira-Frommer, A. J. Treves, D. Zippel, Orit Itzhaki, L. Hershkovitz, D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, B. Shalmon, I. Hardan, R. Catane, G. Markel, S. Apter, A. Ben-Nun, I. Kuchuk, A. Shimoni, A. Nagler and J. Schachter, Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients,, Clin. Cancer Res., 16 (2010), 2646. doi: 10.1158/1078-0432.CCR-10-0041.

[4]

C. Bourquin, S. Schreiber, S. Beck, G. Hartmann and S. Endres, Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer,, Int. J. Cancer., 118 (2006), 2790. doi: 10.1002/ijc.21681.

[5]

S. Bunimovich-Mendrazitsky, H. Byrne and L. Stone, Mathematical model of pulsed immunotherapy for superficial bladder cancer,, Bull. Math. Biol., 70 (2008), 2055. doi: 10.1007/s11538-008-9344-z.

[6]

S. Bunimovich-Mendrazitsky, E. Shochat and L. Stone, Mathematical model of BCG immunotherapy in superficial bladder cancer,, Bull. Math. Biol., 69 (2007), 1847. doi: 10.1007/s11538-007-9195-z.

[7]

F. Castiglione and B. Piccoli, Cancer immunotherapy, mathematical modeling and optimal control,, J. Theor. Biol., 247 (2007), 723. doi: 10.1016/j.jtbi.2007.04.003.

[8]

D. Catovsky, S. Richards, E. Matutes, D. Oscier, M. J. S. Dyer, R. F. Bezares, A. R. Pettitt, T. Hamblin, D. W. Milligan, J. A. Child, M. S. Hamilton, C. E. Dearden, A. G. Smith, A. G. Bosanquet, Z. Davis, V. Brito-Babapulle, M, Else, R. Wade and P. Hillmen, Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial,, Lancet, 370 (2007), 230. doi: 10.1016/S0140-6736(07)61125-8.

[9]

L. G. de Pillis, W. Gu and A. E. Radunskaya, Mixed immunotherapy and chemotherapy of tumors: Modeling, applications, and biological interpretations,, J. Theor. Biol., 238 (2006), 841. doi: 10.1016/j.jtbi.2005.06.037.

[10]

L. G. de Pillis and A. E. Radunskaya, A mathematical model of immune response to tumor invasion,, in Computational Fluid and Solid Mechanics (ed. K.J. Bathe), (2003), 1661. doi: 10.1016/B978-008044046-0.50404-8.

[11]

L. G. de Pillis and A. E. Radunskaya, The dynamics of an optimally controlled tumor model: A case study,, Math. Comput. Model., 37 (2003), 1221. doi: 10.1016/S0895-7177(03)00133-X.

[12]

A. Diefenbach, E. R. Jensen, A. M. Jamieson and D. H. Raulet, Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity,, Nature, 413 (2001), 165.

[13]

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,, Science, 298 (2002), 850. doi: 10.1126/science.1076514.

[14]

M. E. Dudley, J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. M. Sherry, F. M. Marincola, S. F. Leitman, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, A. Nahvi, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma,, Immunother., 25 (2008), 243. doi: 10.1097/00002371-200205000-00007.

[15]

M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. E. White and S. A. Rosenberg, Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens,, J. Clin. Oncol., 26 (2008), 5233. doi: 10.1200/JCO.2008.16.5449.

[16]

T. Fehm, V. Mueller, R. Marches, G. Klein, B. Gueckel, H. Neubauer, E. Solomayer and S. Becker, Tumor cell dormancy: Implications for the biology and treatment of breast cancer,, APMIS, 116 (2008), 742. doi: 10.1111/j.1600-0463.2008.01047.x.

[17]

J. Folkman and R. Kalluri, Cancer without disease,, Nature, 427 (2004). doi: 10.1038/427787a.

[18]

D. I. Gabrilovich, Combination of chemotherapy and immunotherapy for cancer: A paradigm revisited,, Lancet Oncol., 8 (2007), 2. doi: 10.1016/S1470-2045(06)70985-8.

[19]

M. Ghielmini, Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example,, Hematology, 2005 (2005), 321. doi: 10.1182/asheducation-2005.1.321.

[20]

H. S. Hochster, M. M. Oken, J. N. Winter, L. I. Gordon, B. G. Raphael, J. M. Bennett and P. A. Cassileth, Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up-a report from the eastern cooperative oncology group,, J. Clin. Oncol., 18 (2000), 987.

[21]

M. Itik and S. P. Banks, Chaos in a three-dimensional cancer model,, Internat. J. Bifur. Chaos Appl. Sci. Engrg., 20 (2010), 71. doi: 10.1142/S0218127410025417.

[22]

D. Kirschner and J. C. Panetta, Modeling immunotherapy of the tumor-immune interaction,, J. Math. Biol., 37 (1998), 235. doi: 10.1007/s002850050127.

[23]

Y. A. Kuznetsov, Elements of Applied Bifurcation Theory,, $2^{nd}$ edition, (1998).

[24]

V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson, Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis,, Bull. Math. Biol., 56 (1994), 295.

[25]

H. Li, C. Wang, J. Yu, S. Cao, F. Wei, W. Zhang, Y. Han and X. Ren, Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery,, Cytotherapy, 11 (2009), 1076.

[26]

P. Lissoni, M. Chilelli, S. Villa, L. Cerizza and G. Tancini, Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial,, J. Pineal Res., 35 (2003), 12. doi: 10.1034/j.1600-079X.2003.00032.x.

[27]

J. H. Machiels, R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye and E. M. Jaffee, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice,, Cancer Res., 61 (2001), 3689.

[28]

F. K. Nani and M. N. Oguztoreli, Modelling and simulation of Rosenberg-type adoptive cellular immunotherapy,, IMA J. Math. Med. Biol., 11 (1994), 107. doi: 10.1093/imammb/11.2.107.

[29]

A. K. Nowak, B. W. S. Robinson and R. A. Lake, Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,, Cancer Res., 63 (2003), 4490.

[30]

J. C. Panetta, A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment,, Bull. Math. Biol., 58 (1996), 425. doi: 10.1007/BF02460591.

[31]

A. S. Perelson and G. Weisbuch, Immunology for physicists,, Rev. Mod. Phys., 69 (1997), 1219. doi: 10.1103/RevModPhys.69.1219.

[32]

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg and J. C. Yang, Localization $of ^{111}$Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,, Cancer, 73 (1994), 1731.

[33]

R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H. I. Cho, S. Antonia, S. Altiok, E. Celis and D. I. Gabrilovich, Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,, J. Clin Invest., 120 (2010), 1111. doi: 10.1172/JCI40269.

[34]

S. A. Rosenberg, Development of effective immunotherapy for the treatment of patients with cancer,, J. Am. Coll. Surg., 198 (2004), 685. doi: 10.1016/j.jamcollsurg.2004.01.025.

[35]

S. A. Rosenberg and M. E. Dudley, Adoptive cell therapy for the treatment of patients with metastatic melanoma,, Curr. Opin. Immunol., 21 (2009), 233. doi: 10.1016/j.coi.2009.03.002.

[36]

S. Suki, H. Kantarjian, V. Gandhi, E. Estey, S. O'Brien, M. Beran, M. B. Rios, W. Plunkett and M. Keating, Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia,, Cancer, 72 (1993), 2155. doi: 10.1002/1097-0142(19931001)72:7<2155::AID-CNCR2820720715>3.0.CO;2-V.

[37]

T. Trisilowati, S. McCue and D. Mallet, Numerical solution of an optimal control model of dendritic cell treatment of a growing tumour,, ANZIAM J., 54 (2013).

[38]

H. C. Wei, A numerical study of a mathematical model of pulsed immunotherapy for superficial bladder cancer,, Jpn. J. Ind. Appl. Math., 30 (2013), 441. doi: 10.1007/s13160-013-0107-3.

[39]

H. C. Wei, S. F. Hwang, J. T. Lin and T. J. Chen, The role of initial tumor biomass size in a mathematical model of periodically pulsed chemotherapy,, Comput. Math. Appl., 61 (2011), 3117. doi: 10.1016/j.camwa.2011.03.102.

[40]

H. C. Wei and J. T. Lin, Periodically pulsed immunotherapy in a mathematical model of tumor-immune interaction,, Internat. J. Bifur. Chaos Appl. Sci. Engrg., 23 (2013). doi: 10.1142/S0218127413500685.

show all references

References:
[1]

N. Almog, Molecular mechanisms underlying tumor dormancy,, Cancer Lett., 294 (2010), 139. doi: 10.1016/j.canlet.2010.03.004.

[2]

A. J. Barrett and B. N. Savani, Does chemotherapy modify the immune surveillance of hematological malignancies?, Leukemia, 23 (2009), 53. doi: 10.1038/leu.2008.273.

[3]

M. J. Besser, R. Shapira-Frommer, A. J. Treves, D. Zippel, Orit Itzhaki, L. Hershkovitz, D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, B. Shalmon, I. Hardan, R. Catane, G. Markel, S. Apter, A. Ben-Nun, I. Kuchuk, A. Shimoni, A. Nagler and J. Schachter, Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients,, Clin. Cancer Res., 16 (2010), 2646. doi: 10.1158/1078-0432.CCR-10-0041.

[4]

C. Bourquin, S. Schreiber, S. Beck, G. Hartmann and S. Endres, Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancer,, Int. J. Cancer., 118 (2006), 2790. doi: 10.1002/ijc.21681.

[5]

S. Bunimovich-Mendrazitsky, H. Byrne and L. Stone, Mathematical model of pulsed immunotherapy for superficial bladder cancer,, Bull. Math. Biol., 70 (2008), 2055. doi: 10.1007/s11538-008-9344-z.

[6]

S. Bunimovich-Mendrazitsky, E. Shochat and L. Stone, Mathematical model of BCG immunotherapy in superficial bladder cancer,, Bull. Math. Biol., 69 (2007), 1847. doi: 10.1007/s11538-007-9195-z.

[7]

F. Castiglione and B. Piccoli, Cancer immunotherapy, mathematical modeling and optimal control,, J. Theor. Biol., 247 (2007), 723. doi: 10.1016/j.jtbi.2007.04.003.

[8]

D. Catovsky, S. Richards, E. Matutes, D. Oscier, M. J. S. Dyer, R. F. Bezares, A. R. Pettitt, T. Hamblin, D. W. Milligan, J. A. Child, M. S. Hamilton, C. E. Dearden, A. G. Smith, A. G. Bosanquet, Z. Davis, V. Brito-Babapulle, M, Else, R. Wade and P. Hillmen, Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial,, Lancet, 370 (2007), 230. doi: 10.1016/S0140-6736(07)61125-8.

[9]

L. G. de Pillis, W. Gu and A. E. Radunskaya, Mixed immunotherapy and chemotherapy of tumors: Modeling, applications, and biological interpretations,, J. Theor. Biol., 238 (2006), 841. doi: 10.1016/j.jtbi.2005.06.037.

[10]

L. G. de Pillis and A. E. Radunskaya, A mathematical model of immune response to tumor invasion,, in Computational Fluid and Solid Mechanics (ed. K.J. Bathe), (2003), 1661. doi: 10.1016/B978-008044046-0.50404-8.

[11]

L. G. de Pillis and A. E. Radunskaya, The dynamics of an optimally controlled tumor model: A case study,, Math. Comput. Model., 37 (2003), 1221. doi: 10.1016/S0895-7177(03)00133-X.

[12]

A. Diefenbach, E. R. Jensen, A. M. Jamieson and D. H. Raulet, Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity,, Nature, 413 (2001), 165.

[13]

M. E. Dudley, J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, M. R. Robinson, M. Raffeld, P. Duray, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,, Science, 298 (2002), 850. doi: 10.1126/science.1076514.

[14]

M. E. Dudley, J. R. Wunderlich, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. M. Sherry, F. M. Marincola, S. F. Leitman, C. A. Seipp, L. Rogers-Freezer, K. E. Morton, A. Nahvi, S. A. Mavroukakis, D. E. White and S. A. Rosenberg, A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma,, Immunother., 25 (2008), 243. doi: 10.1097/00002371-200205000-00007.

[15]

M. E. Dudley, J. C. Yang, R. Sherry, M. S. Hughes, R. Royal, U. Kammula, P. F. Robbins, J. Huang, D. E. Citrin, S. F. Leitman, J. Wunderlich, N. P. Restifo, A. Thomasian, S. G. Downey, F. O. Smith, J. Klapper, K. Morton, C. Laurencot, D. E. White and S. A. Rosenberg, Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens,, J. Clin. Oncol., 26 (2008), 5233. doi: 10.1200/JCO.2008.16.5449.

[16]

T. Fehm, V. Mueller, R. Marches, G. Klein, B. Gueckel, H. Neubauer, E. Solomayer and S. Becker, Tumor cell dormancy: Implications for the biology and treatment of breast cancer,, APMIS, 116 (2008), 742. doi: 10.1111/j.1600-0463.2008.01047.x.

[17]

J. Folkman and R. Kalluri, Cancer without disease,, Nature, 427 (2004). doi: 10.1038/427787a.

[18]

D. I. Gabrilovich, Combination of chemotherapy and immunotherapy for cancer: A paradigm revisited,, Lancet Oncol., 8 (2007), 2. doi: 10.1016/S1470-2045(06)70985-8.

[19]

M. Ghielmini, Multimodality therapies and optimal schedule of antibodies: rituximab in lymphoma as an example,, Hematology, 2005 (2005), 321. doi: 10.1182/asheducation-2005.1.321.

[20]

H. S. Hochster, M. M. Oken, J. N. Winter, L. I. Gordon, B. G. Raphael, J. M. Bennett and P. A. Cassileth, Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and long-term follow-up-a report from the eastern cooperative oncology group,, J. Clin. Oncol., 18 (2000), 987.

[21]

M. Itik and S. P. Banks, Chaos in a three-dimensional cancer model,, Internat. J. Bifur. Chaos Appl. Sci. Engrg., 20 (2010), 71. doi: 10.1142/S0218127410025417.

[22]

D. Kirschner and J. C. Panetta, Modeling immunotherapy of the tumor-immune interaction,, J. Math. Biol., 37 (1998), 235. doi: 10.1007/s002850050127.

[23]

Y. A. Kuznetsov, Elements of Applied Bifurcation Theory,, $2^{nd}$ edition, (1998).

[24]

V. A. Kuznetsov, I. A. Makalkin, M. A. Taylor and A. S. Perelson, Nonlinear dynamics of immunogenic tumors: Parameter estimation and global bifurcation analysis,, Bull. Math. Biol., 56 (1994), 295.

[25]

H. Li, C. Wang, J. Yu, S. Cao, F. Wei, W. Zhang, Y. Han and X. Ren, Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery,, Cytotherapy, 11 (2009), 1076.

[26]

P. Lissoni, M. Chilelli, S. Villa, L. Cerizza and G. Tancini, Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial,, J. Pineal Res., 35 (2003), 12. doi: 10.1034/j.1600-079X.2003.00032.x.

[27]

J. H. Machiels, R. T. Reilly, L. A. Emens, A. M. Ercolini, R. Y. Lei, D. Weintraub, F. I. Okoye and E. M. Jaffee, Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice,, Cancer Res., 61 (2001), 3689.

[28]

F. K. Nani and M. N. Oguztoreli, Modelling and simulation of Rosenberg-type adoptive cellular immunotherapy,, IMA J. Math. Med. Biol., 11 (1994), 107. doi: 10.1093/imammb/11.2.107.

[29]

A. K. Nowak, B. W. S. Robinson and R. A. Lake, Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors,, Cancer Res., 63 (2003), 4490.

[30]

J. C. Panetta, A mathematical model of periodically pulsed chemotherapy: Tumor recurrence and metastasis in a competitive environment,, Bull. Math. Biol., 58 (1996), 425. doi: 10.1007/BF02460591.

[31]

A. S. Perelson and G. Weisbuch, Immunology for physicists,, Rev. Mod. Phys., 69 (1997), 1219. doi: 10.1103/RevModPhys.69.1219.

[32]

B. A. Pockaj, R. M. Sherry, J. P. Wei, J. R. Yannelli, C. S. Carter, S. F. Leitman, J. A. Carasquillo, S. M. Steinberg, S. A. Rosenberg and J. C. Yang, Localization $of ^{111}$Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response,, Cancer, 73 (1994), 1731.

[33]

R. Ramakrishnan, D. Assudani, S. Nagaraj, T. Hunter, H. I. Cho, S. Antonia, S. Altiok, E. Celis and D. I. Gabrilovich, Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice,, J. Clin Invest., 120 (2010), 1111. doi: 10.1172/JCI40269.

[34]

S. A. Rosenberg, Development of effective immunotherapy for the treatment of patients with cancer,, J. Am. Coll. Surg., 198 (2004), 685. doi: 10.1016/j.jamcollsurg.2004.01.025.

[35]

S. A. Rosenberg and M. E. Dudley, Adoptive cell therapy for the treatment of patients with metastatic melanoma,, Curr. Opin. Immunol., 21 (2009), 233. doi: 10.1016/j.coi.2009.03.002.

[36]

S. Suki, H. Kantarjian, V. Gandhi, E. Estey, S. O'Brien, M. Beran, M. B. Rios, W. Plunkett and M. Keating, Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia,, Cancer, 72 (1993), 2155. doi: 10.1002/1097-0142(19931001)72:7<2155::AID-CNCR2820720715>3.0.CO;2-V.

[37]

T. Trisilowati, S. McCue and D. Mallet, Numerical solution of an optimal control model of dendritic cell treatment of a growing tumour,, ANZIAM J., 54 (2013).

[38]

H. C. Wei, A numerical study of a mathematical model of pulsed immunotherapy for superficial bladder cancer,, Jpn. J. Ind. Appl. Math., 30 (2013), 441. doi: 10.1007/s13160-013-0107-3.

[39]

H. C. Wei, S. F. Hwang, J. T. Lin and T. J. Chen, The role of initial tumor biomass size in a mathematical model of periodically pulsed chemotherapy,, Comput. Math. Appl., 61 (2011), 3117. doi: 10.1016/j.camwa.2011.03.102.

[40]

H. C. Wei and J. T. Lin, Periodically pulsed immunotherapy in a mathematical model of tumor-immune interaction,, Internat. J. Bifur. Chaos Appl. Sci. Engrg., 23 (2013). doi: 10.1142/S0218127413500685.

[1]

Ana I. Muñoz, José Ignacio Tello. Mathematical analysis and numerical simulation of a model of morphogenesis. Mathematical Biosciences & Engineering, 2011, 8 (4) : 1035-1059. doi: 10.3934/mbe.2011.8.1035
[2]

Ben Sheller, Domenico D'Alessandro. Analysis of a cancer dormancy model and control of immuno-therapy. Mathematical Biosciences & Engineering, 2015, 12 (5) : 1037-1053. doi: 10.3934/mbe.2015.12.1037
[3]

Blessing O. Emerenini, Stefanie Sonner, Hermann J. Eberl. Mathematical analysis of a quorum sensing induced biofilm dispersal model and numerical simulation of hollowing effects. Mathematical Biosciences & Engineering, 2017, 14 (3) : 625-653. doi: 10.3934/mbe.2017036
[4]

Sergio Amat, Pablo Pedregal. On a variational approach for the analysis and numerical simulation of ODEs. Discrete & Continuous Dynamical Systems - A, 2013, 33 (4) : 1275-1291. doi: 10.3934/dcds.2013.33.1275
[5]

Qiaolin He. Numerical simulation and self-similar analysis of singular solutions of Prandtl equations. Discrete & Continuous Dynamical Systems - B, 2010, 13 (1) : 101-116. doi: 10.3934/dcdsb.2010.13.101
[6]

Rolf Rannacher. A short course on numerical simulation of viscous flow: Discretization, optimization and stability analysis. Discrete & Continuous Dynamical Systems - S, 2012, 5 (6) : 1147-1194. doi: 10.3934/dcdss.2012.5.1147
[7]

Verónica Anaya, Mostafa Bendahmane, Mauricio Sepúlveda. Mathematical and numerical analysis for Predator-prey system in a polluted environment. Networks & Heterogeneous Media, 2010, 5 (4) : 813-847. doi: 10.3934/nhm.2010.5.813
[8]

Laurent Boudin, Bérénice Grec, Francesco Salvarani. A mathematical and numerical analysis of the Maxwell-Stefan diffusion equations. Discrete & Continuous Dynamical Systems - B, 2012, 17 (5) : 1427-1440. doi: 10.3934/dcdsb.2012.17.1427
[9]

Alexander S. Bratus, Svetlana Yu. Kovalenko, Elena Fimmel. On viable therapy strategy for a mathematical spatial cancer model describing the dynamics of malignant and healthy cells. Mathematical Biosciences & Engineering, 2015, 12 (1) : 163-183. doi: 10.3934/mbe.2015.12.163
[10]

Yuncherl Choi, Jongmin Han, Chun-Hsiung Hsia. Bifurcation analysis of the damped Kuramoto-Sivashinsky equation with respect to the period. Discrete & Continuous Dynamical Systems - B, 2015, 20 (7) : 1933-1957. doi: 10.3934/dcdsb.2015.20.1933
[11]

Toshiyuki Ogawa, Takashi Okuda. Bifurcation analysis to Swift-Hohenberg equation with Steklov type boundary conditions. Discrete & Continuous Dynamical Systems - A, 2009, 25 (1) : 273-297. doi: 10.3934/dcds.2009.25.273
[12]

José Ignacio Tello. Mathematical analysis of a model of morphogenesis. Discrete & Continuous Dynamical Systems - A, 2009, 25 (1) : 343-361. doi: 10.3934/dcds.2009.25.343
[13]

Laurence Cherfils, Madalina Petcu, Morgan Pierre. A numerical analysis of the Cahn-Hilliard equation with dynamic boundary conditions. Discrete & Continuous Dynamical Systems - A, 2010, 27 (4) : 1511-1533. doi: 10.3934/dcds.2010.27.1511
[14]

Rodrigue Gnitchogna Batogna, Abdon Atangana. Generalised class of Time Fractional Black Scholes equation and numerical analysis. Discrete & Continuous Dynamical Systems - S, 2019, 12 (3) : 435-445. doi: 10.3934/dcdss.2019028
[15]

Amina Eladdadi, Noura Yousfi, Abdessamad Tridane. Preface: Special issue on cancer modeling, analysis and control. Discrete & Continuous Dynamical Systems - B, 2013, 18 (4) : i-iii. doi: 10.3934/dcdsb.2013.18.4i
[16]

Xiaoli Yang, Jin Liang, Bei Hu. Minimization of carbon abatement cost: Modeling, analysis and simulation. Discrete & Continuous Dynamical Systems - B, 2017, 22 (7) : 2939-2969. doi: 10.3934/dcdsb.2017158
[17]

Sun Yi, Patrick W. Nelson, A. Galip Ulsoy. Delay differential equations via the matrix lambert w function and bifurcation analysis: application to machine tool chatter. Mathematical Biosciences & Engineering, 2007, 4 (2) : 355-368. doi: 10.3934/mbe.2007.4.355
[18]

Heiko Enderling, Alexander R.A. Anderson, Mark A.J. Chaplain, Glenn W.A. Rowe. Visualisation of the numerical solution of partial differential equation systems in three space dimensions and its importance for mathematical models in biology. Mathematical Biosciences & Engineering, 2006, 3 (4) : 571-582. doi: 10.3934/mbe.2006.3.571
[19]

Kimberly Fessel, Jeffrey B. Gaither, Julie K. Bower, Trudy Gaillard, Kwame Osei, Grzegorz A. Rempała. Mathematical analysis of a model for glucose regulation. Mathematical Biosciences & Engineering, 2016, 13 (1) : 83-99. doi: 10.3934/mbe.2016.13.83
[20]

Avner Friedman, Harsh Vardhan Jain. A partial differential equation model of metastasized prostatic cancer. Mathematical Biosciences & Engineering, 2013, 10 (3) : 591-608. doi: 10.3934/mbe.2013.10.591

2017 Impact Factor: 0.972

Tools

Metrics

  • PDF downloads (37)
  • HTML views (0)
  • Cited by (1)

Other articles
by authors

[Back to Top]

Copyright © 2019 American Institute of Mathematical Sciences